1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Macular Degeneration - Pipeline Review, H2 2013

Macular Degeneration - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 357 pages

Macular Degeneration - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Macular Degeneration - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Macular Degeneration.
- A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Macular Degeneration.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Macular Degeneration pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Macular Degeneration - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Macular Degeneration Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Macular Degeneration 13
Macular Degeneration Therapeutics under Development by Companies 15
Macular Degeneration Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Macular Degeneration Therapeutics - Products under Development by Companies 28
Macular Degeneration Therapeutics - Products under Investigation by Universities/Institutes 35
Companies Involved in Macular Degeneration Therapeutics Development 36
Alcon, Inc. 36
Genzyme Corporation 37
Johnson and Johnson 38
F. Hoffmann-La Roche Ltd. 39
Bausch and Lomb Incorporated 40
Allergan, Inc. 41
Shionogi and Co., Ltd. 42
pSivida Corp. 43
Advanced Cell Technology, Inc. 44
GlaxoSmithKline plc 45
Genentech, Inc. 46
Quark Pharmaceuticals, Inc. 47
Lux Biosciences, Inc. 48
Optherion, Inc. 49
RetinaPharma Technologies, Inc. 50
Novartis AG 51
Pfizer Inc. 52
iCo Therapeutics Inc. 53
Lpath, Inc. 54
Mesoblast Ltd 55
BioDiem Ltd 56
ReGenX Biosciences, LLC 57
Circadian Technologies Limited 58
Ophthotech Corp. 59
OXiGENE, Inc. 60
Alexion Pharmaceuticals, Inc. 61
Zenotech Laboratories Limited 62
Regeneron Pharmaceuticals, Inc. 63
NeoStem, Inc. 64
Hanall Pharmaceutical Co., Ltd. 65
Sirion Therapeutics, Inc. 66
Summit Corporation plc 67
ThromboGenics NV 68
PolyMedix, Inc. 69
e-Therapeutics plc 70
NanoCarrier Co., Ltd. 71
R-Tech Ueno, Ltd. 72
Paloma Pharmaceuticals, Inc. 73
Digna Biotech, S.L. 74
Ceregene, Inc. 75
Affitech A/S 76
Ora Bio Ltd. 77
Foamix Ltd. 78
Molecular Partners AG 79
Acucela Inc. 80
Aciont Inc. 81
Neovacs SA 82
Senju Pharmaceutical Co., Ltd. 83
InCode BioPharmaceutics, Inc. 84
OcuCure Therapeutics, Inc. 85
Neurotech Pharmaceuticals, Inc. 86
Gene Signal International SA. 87
Promedior, Inc. 88
Amalyte Pharmaceuticals, LLC 89
Iconic Therapeutics, Inc. 90
Inotek Pharmaceuticals Corporation 91
Indus Biotech Private Limited 92
Cardax Pharmaceuticals, Inc. 93
Intellect Neurosciences, Inc. 94
Omeros Corporation 95
Angstrom Pharmaceuticals, Inc. 96
FirstString Research, Inc. 97
Stemedica Cell Technologies, Inc. 98
Alimera Sciences, Inc. 99
Biovista Inc. 100
Sirnaomics, Inc. 101
Resolvyx Pharmaceuticals, Inc 102
Charlesson LLC. 103
MacuCLEAR, Inc. 104
TRACON Pharmaceuticals, Inc. 105
PanOptica, Inc. 106
OHR Pharmaceutical Inc. 107
Targa Therapeutics Corp. 108
Pfenex Inc. 109
SelectX Pharmaceuticals, Inc. 110
Icon Bioscience, Inc. 111
EyeGene, Inc. 112
Varinel, Inc. 113
Macular Degeneration - Therapeutics Assessment 114
Assessment by Monotherapy Products 114
Assessment by Route of Administration 115
Assessment by Molecule Type 118
Drug Profiles 121
GSK-933776 - Drug Profile 121
volociximab - Drug Profile 122
lampalizumab - Drug Profile 125
ranibizumab - Drug Profile 126
ranibizumab - Drug Profile 129
Lpathomab - Drug Profile 132
iSONEP - Drug Profile 133
emixustat - Drug Profile 135
PMX-20005 - Drug Profile 137
NADPH Oxidase Inhibitor - Drug Profile 138
P-17 - Drug Profile 139
disitertide - Drug Profile 141
unoprostone - Drug Profile 143
AL-78898A - Drug Profile 144
ocriplasmin - Drug Profile 146
Eylea - Drug Profile 149
CERE-140 - Drug Profile 152
ARC-1905 - Drug Profile 153
E-10030 - Drug Profile 155
PARP Inhibitors - Drug Profile 157
INO-6001 - Drug Profile 158
SIR-1076 - Drug Profile 159
SIR-1047 - Drug Profile 160
TKI - Drug Profile 161
AM-1101 - Drug Profile 162
INDUS-815C - Drug Profile 163
NT-501 - Drug Profile 164
TRC-093 - Drug Profile 166
NT-503 - Drug Profile 167
ETX-6201 - Drug Profile 168
bertilimumab - Drug Profile 169
OMS-721 - Drug Profile 171
PF-655 - Drug Profile 173
MC-1101 - Drug Profile 175
MC-1101 - Drug Profile 177
VEGF Kinoid - Drug Profile 179
SAR-402663 - Drug Profile 180
RX-20001 - Drug Profile 181
AL-39324 - Drug Profile 182
PF-04382923 - Drug Profile 183
OC-10X - Drug Profile 184
fluocinolone acetonide - Drug Profile 185
SMT-D004 - Drug Profile 187
CLT-003 - Drug Profile 188
Recombinant Protective Human Complement Factor H Protein - Drug Profile 189
Granzyme B/VEGF - Drug Profile 190
ALXN-1102 - Drug Profile 191
VAR-10200 - Drug Profile 192
TA-106 - Drug Profile 193
A-6 - Drug Profile 194
hI-con1 - Drug Profile 196
aganirsen - Drug Profile 197
P-529 - Drug Profile 199
tandospirone citrate - Drug Profile 202
HC3-1496 - Drug Profile 203
siRNA Micelle - Drug Profile 204
TRC-105 - Drug Profile 205
MP-0112 - Drug Profile 207
PGN-635 - Drug Profile 209
HL-036 - Drug Profile 210
squalamine lactate - Drug Profile 211
IN-N01 - Drug Profile 213
MTP-131 - Drug Profile 214
fosbretabulin disodium - Drug Profile 216
pazopanib hydrochloride - Drug Profile 219
BDM-E - Drug Profile 222
VGX-300 - Drug Profile 224
SIR-1046 - Drug Profile 225
RTU-007 - Drug Profile 226
CNTO-2476 - Drug Profile 227
Retinal Pigment Epithelium (RPE) Program - Drug Profile 229
KH-902 - Drug Profile 231
KH-902 - Drug Profile 233
retinylamine - Drug Profile 235
BVA-301 - Drug Profile 236
ORA-102 - Drug Profile 237
ETX-6991 - Drug Profile 238
Drug For Age Related Macular Degeneration - Drug Profile 239
LX-213 - Drug Profile 240
OpRegen - Drug Profile 241
LFG-316 - Drug Profile 242
bromfenac Adjunct - Drug Profile 243
PRM-167 - Drug Profile 244
Drug For Wet Age Related Macular Degeneration - Drug Profile 245
Mesenchymal Precursor Cells For Macular Degeneration - Drug Profile 246
Drug For Ocular Diseases - Drug Profile 247
STP-601 - Drug Profile 248
VEGF/rGel - Drug Profile 249
XV-615 - Drug Profile 251
PAN-90806 - Drug Profile 252
EG-Mirotin - Drug Profile 254
VSEL for Macular Degeneration and Glaucoma - Drug Profile 256
S-646240 - Drug Profile 257
RST-001 - Drug Profile 258
INO-6002 - Drug Profile 259
EGP-Wet Age Related Macular Degeneration - Drug Profile 260
ranibizumab Biosimilar - Drug Profile 261
NT-506 - Drug Profile 262
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 263
Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile 264
ARMD Program - Drug Profile 265
IN-N01-OX2 - Drug Profile 266
Anti-Angiogenic Compounds - Drug Profile 267
SNJ-1945 - Drug Profile 268
Cell Migration Inhibitors - Drug Profile 269
Metalloproteinase Inhibitors - Drug Profile 270
PF-05206388 - Drug Profile 271
disitertide Ophthalmic - Drug Profile 272
P-17 Ophthalmic - Drug Profile 273
Age-Related Macular Degeneration Program - Drug Profile 274
OpRegen Plus - Drug Profile 275
RNAi Targeting Vascular Endothelial Growth Factor - Drug Profile 276
KN-014 - Drug Profile 277
RC-1 Alpha - Drug Profile 278
Macular Degeneration Therapeutics - Drug Profile Updates 279
Macular Degeneration Therapeutics - Discontinued Products 333
Macular Degeneration Therapeutics - Dormant Products 334
Macular Degeneration - Product Development Milestones 339
Featured News and Press Releases 339
Appendix 348
Methodology 348
Coverage 348
Secondary Research 348
Primary Research 348
Expert Panel Validation 348
Contact Us 349
Disclaimer 349



List of Tables

Number of Products Under Development for Macular Degeneration, H2 2013 21
Products under Development for Macular Degeneration - Comparative Analysis, H2 2013 22
Number of Products under Development by Companies, H2 2013 24
Number of Products under Development by Companies, H2 2013 (Contd..1) 25
Number of Products under Development by Companies, H2 2013 (Contd..2) 26
Number of Products under Development by Companies, H2 2013 (Contd..3) 27
Number of Products under Development by Companies, H2 2013 (Contd..4) 28
Number of Products under Development by Companies, H2 2013 (Contd..5) 29
Number of Products under Investigation by Universities/Institutes, H2 2013 31
Comparative Analysis by Late Stage Development, H2 2013 32
Comparative Analysis by Mid Clinical Stage Development, H2 2013 33
Comparative Analysis by Early Clinical Stage Development, H2 2013 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 35
Products under Development by Companies, H2 2013 36
Products under Development by Companies, H2 2013 (Contd..1) 37
Products under Development by Companies, H2 2013 (Contd..2) 38
Products under Development by Companies, H2 2013 (Contd..3) 39
Products under Development by Companies, H2 2013 (Contd..4) 40
Products under Development by Companies, H2 2013 (Contd..5) 41
Products under Development by Companies, H2 2013 (Contd..6) 42
Products under Investigation by Universities/Institutes, H2 2013 43
Alcon, Inc., H2 2013 44
Genzyme Corporation, H2 2013 45
Johnson and Johnson, H2 2013 46
F. Hoffmann-La Roche Ltd., H2 2013 47
Bausch and Lomb Incorporated, H2 2013 48
Allergan, Inc., H2 2013 49
Shionogi and Co., Ltd., H2 2013 50
pSivida Corp., H2 2013 51
Advanced Cell Technology, Inc., H2 2013 52
GlaxoSmithKline plc, H2 2013 53
Genentech, Inc., H2 2013 54
Quark Pharmaceuticals, Inc., H2 2013 55
Lux Biosciences, Inc., H2 2013 56
Optherion, Inc., H2 2013 57
RetinaPharma Technologies, Inc., H2 2013 58
Novartis AG, H2 2013 59
Pfizer Inc., H2 2013 60
iCo Therapeutics Inc., H2 2013 61
Lpath, Inc., H2 2013 62
Mesoblast Ltd, H2 2013 63
BioDiem Ltd, H2 2013 64
ReGenX Biosciences, LLC, H2 2013 65
Circadian Technologies Limited, H2 2013 66
Ophthotech Corp., H2 2013 67
OXiGENE, Inc., H2 2013 68
Alexion Pharmaceuticals, Inc., H2 2013 69
Zenotech Laboratories Limited, H2 2013 70
Regeneron Pharmaceuticals, Inc., H2 2013 71
NeoStem, Inc., H2 2013 72
Hanall Pharmaceutical Co., Ltd., H2 2013 73
Sirion Therapeutics, Inc., H2 2013 74
Summit Corporation plc, H2 2013 75
ThromboGenics NV, H2 2013 76
PolyMedix, Inc., H2 2013 77
e-Therapeutics plc, H2 2013 78
NanoCarrier Co., Ltd., H2 2013 79
R-Tech Ueno, Ltd., H2 2013 80
Paloma Pharmaceuticals, Inc., H2 2013 81
Digna Biotech, S.L., H2 2013 82
Ceregene, Inc., H2 2013 83
Affitech A/S, H2 2013 84
Ora Bio Ltd., H2 2013 85
Foamix Ltd., H2 2013 86
Molecular Partners AG, H2 2013 87
Acucela Inc., H2 2013 88
Aciont Inc., H2 2013 89
Neovacs SA, H2 2013 90
Senju Pharmaceutical Co., Ltd., H2 2013 91
InCode BioPharmaceutics, Inc., H2 2013 92
OcuCure Therapeutics, Inc., H2 2013 93
Neurotech Pharmaceuticals, Inc., H2 2013 94
Gene Signal International SA., H2 2013 95
Promedior, Inc., H2 2013 96
Amalyte Pharmaceuticals, LLC, H2 2013 97
Iconic Therapeutics, Inc., H2 2013 98
Inotek Pharmaceuticals Corporation, H2 2013 99
Indus Biotech Private Limited, H2 2013 100
Cardax Pharmaceuticals, Inc., H2 2013 101
Intellect Neurosciences, Inc., H2 2013 102
Omeros Corporation, H2 2013 103
Angstrom Pharmaceuticals, Inc., H2 2013 104
FirstString Research, Inc., H2 2013 105
Stemedica Cell Technologies, Inc., H2 2013 106
Alimera Sciences, Inc., H2 2013 107
Biovista Inc., H2 2013 108
Sirnaomics, Inc., H2 2013 109
Resolvyx Pharmaceuticals, Inc, H2 2013 110
Charlesson LLC., H2 2013 111
MacuCLEAR, Inc., H2 2013 112
TRACON Pharmaceuticals, Inc., H2 2013 113
PanOptica, Inc., H2 2013 114
OHR Pharmaceutical Inc., H2 2013 115
Targa Therapeutics Corp., H2 2013 116
Pfenex Inc., H2 2013 117
SelectX Pharmaceuticals, Inc., H2 2013 118
Icon Bioscience, Inc., H2 2013 119
EyeGene, Inc., H2 2013 120
Varinel, Inc., H2 2013 121
Assessment by Monotherapy Products, H2 2013 122
Assessment by Stage and Route of Administration, H2 2013 125
Assessment by Stage and Molecule Type, H2 2013 128
Macular Degeneration Therapeutics - Drug Profile Updates 287
Macular Degeneration Therapeutics - Discontinued Products 341
Macular Degeneration Therapeutics - Dormant Products 342
Macular Degeneration Therapeutics - Dormant Products (Contd..1) 343
Macular Degeneration Therapeutics - Dormant Products (Contd..2) 344
Macular Degeneration Therapeutics - Dormant Products (Contd..3) 345
Macular Degeneration Therapeutics - Dormant Products (Contd..4) 346



List of Figures

Number of Products under Development for Macular Degeneration, H2 2013 21
Products under Development for Macular Degeneration - Comparative Analysis, H2 2013 22
Products under Development by Companies, H2 2013 23
Products under Investigation by Universities/Institutes, H2 2013 30
Late Stage Products, H2 2013 32
Mid Clinical Stage Products, H2 2013 33
Early Clinical Stage Products, H2 2013 34
Discovery and Pre-Clinical Stage Products, H2 2013 35
Assessment by Monotherapy Products, H2 2013 122
Assessment by Route of Administration, H2 2013 123
Assessment by Stage and Route of Administration, H2 2013 124
Assessment by Molecule Type, H2 2013 126
Assessment by Stage and Molecule Type, H2 2013 127



Companies Mentioned

Alcon, Inc.
Genzyme Corporation
Johnson and Johnson
F. Hoffmann-La Roche Ltd.
Bausch and Lomb Incorporated
Allergan, Inc.
Shionogi and Co., Ltd.
pSivida Corp.
Advanced Cell Technology, Inc.
GlaxoSmithKline plc
Genentech, Inc.
Quark Pharmaceuticals, Inc.
Lux Biosciences, Inc.
Optherion, Inc.
RetinaPharma Technologies, Inc.
Novartis AG
Pfizer Inc.
iCo Therapeutics Inc.
Lpath, Inc.
Mesoblast Ltd
BioDiem Ltd
ReGenX Biosciences, LLC
Circadian Technologies Limited
Ophthotech Corp.
OXiGENE, Inc.
Alexion Pharmaceuticals, Inc.
Zenotech Laboratories Limited
Regeneron Pharmaceuticals, Inc.
NeoStem, Inc.
Hanall Pharmaceutical Co., Ltd.
Sirion Therapeutics, Inc.
Summit Corporation plc
ThromboGenics NV
PolyMedix, Inc.
e-Therapeutics plc
NanoCarrier Co., Ltd.
R-Tech Ueno, Ltd.
Paloma Pharmaceuticals, Inc.
Digna Biotech, S.L.
Ceregene, Inc.
Affitech A/S
Ora Bio Ltd.
Foamix Ltd.
Molecular Partners AG
Acucela Inc.
Aciont Inc.
Neovacs SA
Senju Pharmaceutical Co., Ltd.
InCode BioPharmaceutics, Inc.
OcuCure Therapeutics, Inc.
Neurotech Pharmaceuticals, Inc.
Gene Signal International SA.
Promedior, Inc.
Amalyte Pharmaceuticals, LLC
Iconic Therapeutics, Inc.
Inotek Pharmaceuticals Corporation
Indus Biotech Private Limited
Cardax Pharmaceuticals, Inc.
Intellect Neurosciences, Inc.
Omeros Corporation
Angstrom Pharmaceuticals, Inc.
FirstString Research, Inc.
Stemedica Cell Technologies, Inc.
Alimera Sciences, Inc.
Biovista Inc.
Sirnaomics, Inc.
Resolvyx Pharmaceuticals, Inc
Charlesson LLC.
MacuCLEAR, Inc.
TRACON Pharmaceuticals, Inc.
PanOptica, Inc.
OHR Pharmaceutical Inc.
Targa Therapeutics Corp.
Pfenex Inc.
SelectX Pharmaceuticals, Inc.
Icon Bioscience, Inc.
EyeGene, Inc.
Varinel, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.